Skip to main content
. 2024 Apr 10;12(4):838. doi: 10.3390/biomedicines12040838

Table 7.

The outcomes of using NIPPV compared to using NCPAP.

Variables (Reference) β S.E. p Value Odds Ratio 95% C.I. for Exp (β)
Lower Upper
Air leak 1.253 1.039 0.228 3.500 0.456 26.841
BPD −0.526 0.797 0.509 0.591 0.124 2.818
Moderate to severe BPD −0.441 0.737 0.549 0.643 0.152 2.727
Respiratory support at day 28 −0.610 1.183 0.606 0.543 0.053 5.527
O2 supplement at day 28 −5.741 4.300 0.182 0.003 0.000 14.695
Respiratory support at week 36 −0.872 0.680 0.199 0.418 0.110 1.584
O2 supplement at week 36 −0.452 0.823 0.583 0.636 0.127 3.192
Methylxanthines * −5.096 7089 0.999 0.006 0.000 -
IVH 0.424 0.700 0.544 1.529 0.388 6.024
IVH ≥ grade 3 −4.273 4.326 0.323 0.014 0.000 67.054
PVE 1.101 0.717 0.125 3.008 0.738 12.263
Cystic PVL 1.292 0.980 0.187 3.640 0.534 24.831
Posthemorrhagic hydrocephalus 17.362 5340.852 0.997 34,747,980.8 −0.982 1.006
ROP 1.102 0.886 0.213 3.010 0.531 17.082
ROP ≥ stage 3 2.405 1.369 0.079 11.083 0.757 162.280
NEC 0.619 1.355 0.648 1.858 0.131 26.444
NEC ≥ stage 2 18.139 5499.397 0.997 75,423,990.2 0.000 -
PDA −1.035 1.007 0.304 0.355 0.049 2.558
Early-onset sepsis 0.638 0.719 0.375 1.892 0.462 7.751
Late-onset sepsis −1.072 1.077 0.320 0.342 0.041 2.827
PAH 0.468 0.996 0.638 1.597 0.227 11.255
Death −3.897 2.087 0.062 0.020 0.000 1.214
Higher respiratory support −1.023 0.663 0.123 0.359 0.098 1.318
More than 30 days of ventilator 0.193 0.821 0.814 1.213 0.243 6.063

* Methylxanthines include caffeine and theophylline. S.E., Standard error of mean. C.I., Confidence Interval. p < 0.05. BPD: bronchopulmonary dysplasia; IVH: intraventricular hemorrhage; PVE: periventricular echogenicities; PVL: periventricular leukomalacia; ROP: retinopathy of prematurity; NEC: necrotizing enterocolitis; PDA: patent ductus arteriosus; PAH: pulmonary arterial hypertension.